THE FUNDAMENTALS BEHIND XIENCE ALPINE
The XIENCE Alpine coronary stent system may be used by interventional cardiologists to treat a blockage and open the artery. A stent implant procedure is known as percutaneous coronary intervention (PCI).
XIENCE, which is also described as a drug-eluting stent (DES) or more specifically an everolimus-eluting stent (EES), is a leading DES because of its considerable safety data. XIENCE Alpine is engineered for complex intervention.
Precision in Stent Placement
MULTI-LINK design, with 100% accurate mid-marker to mid-marker stent placement, offers precise deployment
True Center Tip
Flexible tip design with co-axial positioning system (CPS) offers peak performance in complex lesions
Higher Performance Catheter
Catheter is engineered to optimize strength, flexibility and pushability
- Zero-transition distal shaft
- Proprietary skive design
- Robust hypotube with optimized thickness
- Specially formulated outer member
Durable Balloon with Flat Compliance
Thin, dual-layer balloon enables high pressure deployment while maintaining flexibility and strength.
U.S. PATIENT INFORMATION GUIDE
Ensure that patients have the information they need about coronary artery disease and the XIENCE family of stent systems. The XIENCE Patient Information Guide illustrates the stent procedure and outlines the risks and benefits of treatment with XIENCE.
*10,000,000 implants number is based on data of DES implants through Q1 2017. Comparative claim based on unit usage in U.S., Japan, China, India, top 5 Western Europe and Korea. Other leading DES: BSX stents (Promus ElementTM, Promus ElementTM Plus, Promus PremierTM, SynergyTM); MDT stents (ResoluteTM, Resolute IntegrityTM, Resolute OnyxTM); Terumo stents (NoboriTM, Ultimaster®); Biotronik stent (OrsiroTM); and Biosensors stent (BioMatrixTM).
Data on file at Abbott
1. Valgimigli M. Effects of cobalt-chromium everolimus eluting or bare metal stent on fatal and non-fatal cardiovascular events: a patient-level meta analysis. EuroPCR 2014.
2. Bangalore S, et al. BMJ. 2013;347:f6625. doi: 10.1136/bmj.f6625.
3. Palmerini T, et al. JACC. 2014;63:299-307. doi: 10.1016/j.jacc.2013.09.061.
4. Colombo A, et al. JACC. 2002;40:1021-1033.
5. Data on file at Abbott Vascular.
6. Kolandaivelu K, et al. Circulation. 2011;123;1400-1409.
7. Kastrati A, et al. Circulation. 2001;103;2816-2821.
8. Perkins LEL, et al. J Interv Cardiol. 2009;22(s1):S28-S40.
9. Otsuka F, et al. JACC Cardiovasc Interv. 2015;8:1248-1260. doi: 10.1016/j.jcin.2015.03.029.
10. Otsuka F, et al. Circ Cardiovasc Interv. 2014;7:330-342.
11. Ding N, et al. J Interv Cardiol. 2009;22(s1):S18-S27.
12. Joner M, et al. J Am Coll Cardiol. 2008;52(5):333-432. doi: 10.1016/j.jacc.2008.04.030.
13. Guidoin R, et al. ASAIO J. 1994;40(3):M870-M879.